Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Rotigotine: High-Affinity Dopamine D2/D3 Receptor Agonist...

    2026-03-11

    Rotigotine: High-Affinity Dopamine D2/D3 Receptor Agonist for Parkinson's Disease Research

    Executive Summary: Rotigotine is a dopamine D2 and D3 receptor agonist with sub-15 nM affinity, conferring high selectivity for dopaminergic pathways relevant to Parkinson’s disease (PD) models (APExBIO). It shows antiparkinsonian activity and modulates both motor and non-motor symptoms in preclinical assays (Ouchi et al., 2022). Rotigotine demonstrates significant secondary binding to 5-HT1A and adrenergic α2B receptors, supporting expanded pharmacological profiling. The compound is stable as a crystalline solid at -20°C, but solutions should be used promptly for reproducibility. APExBIO provides Rotigotine (A3776) with ≥98% purity, enabling robust cell-based and in vivo workflows (BiperidenShop).

    Biological Rationale

    Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, resulting in both motor dysfunction and non-motor symptoms such as lower urinary tract disturbances (Ouchi et al., 2022). Dopamine receptor agonists are central to modeling, understanding, and treating these deficits in preclinical and translational research settings. Rotigotine, as a dopamine D2/D3 receptor agonist, is used to mimic or compensate for dopaminergic tone reduction in animal and cell-based models. Its high affinity (Ki = 13 nM for D2; 0.71 nM for D3) enables precise engagement of relevant signaling pathways (APExBIO). Rotigotine’s activity at other receptors, including 5-HT1A and α2B adrenergic, allows investigation of off-target or pleiotropic effects in complex neurobiological systems.

    Mechanism of Action of Rotigotine

    Rotigotine acts as an agonist at dopamine D2 and D3 receptors, with documented nanomolar affinity, and also interacts with D1-D5 subtypes at lower potency (Ouchi et al., 2022). Upon binding, it stimulates Gi/o-coupled signaling, resulting in decreased cAMP production and modulation of neuronal excitability. In PD models, this leads to improvement in motor symptoms and normalization of micturition reflexes. Rotigotine’s effect on lower urinary tract function is mediated via supraspinal pathways projecting to the pontine micturition center, as demonstrated by altered intercontraction interval and voiding pressure in 6-OHDA rat models. Secondary interactions with 5-HT1A and α2B adrenergic receptors may contribute to its broader pharmacodynamic profile (APExBIO).

    Evidence & Benchmarks

    • Rotigotine displays high affinity for dopamine D2 (Ki = 13 nM) and D3 (Ki = 0.71 nM) receptors, as measured via radioligand binding assays (APExBIO).
    • In 6-OHDA-induced PD rat models, intravenous rotigotine (0.25 or 0.5 mg/kg) significantly reduced intercontraction interval (ICI) compared to vehicle (p < 0.05) (Ouchi et al., 2022, Table 1A).
    • Voiding pressure (VP) was significantly decreased by 0.5 mg/kg intravenous rotigotine compared to vehicle (p = 0.028), confirming activity in non-motor symptom domains (Ouchi et al., 2022, Table 1B).
    • Subcutaneous rotigotine (0.125–0.5 mg/kg) increased ICI at 2 h post-injection, supporting sustained supraspinal effects (Ouchi et al., 2022).
    • Rotigotine is soluble to ≥58 mg/mL in DMSO and ≥25.25 mg/mL in ethanol, but is insoluble in water, impacting workflow design (APExBIO).
    • Purity is ≥98% (HPLC), and the molecular weight is 315.47 g/mol (APExBIO).

    For a scenario-driven, practical guide to viability and signaling assays using Rotigotine, see this article. This current dossier extends those findings by focusing on quantitative in vivo and receptor-level benchmarks.

    Applications, Limits & Misconceptions

    Rotigotine is a validated tool for modeling dopaminergic dysfunction in cell-based and animal models of Parkinson’s disease. It is routinely used in studies of motor impairment, micturition reflex, and neuroprotection. Its quantitative affinity profile enables reproducible modulation of D2/D3 signaling in vitro and in vivo. The compound’s secondary receptor activity (5-HT1A, α2B) supports expanded pharmacodynamic studies, though this may confound interpretation if off-target effects are not controlled. Purity and solubility support high-confidence data in cell viability, proliferation, and neuroprotection assays (BiperidenPharma), but water insolubility demands careful solvent selection.

    Common Pitfalls or Misconceptions

    • Rotigotine is not suitable for direct therapeutic use in humans without regulatory approval; it is strictly for research purposes (APExBIO).
    • Long-term storage of solutions is not recommended—instability may compromise reproducibility.
    • It is water-insoluble; attempts to dissolve in aqueous buffers result in precipitation and loss of activity.
    • Secondary activity at 5-HT1A and α2B receptors can confound studies if not properly controlled for off-target effects.
    • Rotigotine is not selective for a single dopamine receptor subtype; it also interacts with D1, D4, and D5 at higher concentrations (Ouchi et al., 2022).

    For advanced analytical and stability considerations, see this resource, which is complemented here by updated in vivo efficacy benchmarks and workflow integration tips.

    Workflow Integration & Parameters

    Rotigotine (A3776) from APExBIO is supplied as a crystalline solid at ≥98% purity. For cell-based assays, dissolve to working concentrations in DMSO (≥58 mg/mL) or ethanol (≥25.25 mg/mL); avoid water. Use solutions immediately after preparation and store aliquots at -20°C to preserve integrity. For animal studies, dosing regimens of 0.125–0.5 mg/kg (intravenous or subcutaneous) are validated in PD models (Ouchi et al., 2022). Benchmarking against vehicle controls is required. Purity and supplier reliability are critical; see this comparative article for how APExBIO’s Rotigotine stands out. This dossier clarifies protocol details and extends in vivo efficacy data for translational modeling.

    Conclusion & Outlook

    Rotigotine is a gold-standard dopamine D2/D3 receptor agonist for PD and dopaminergic signaling pathway research. Its high receptor affinity, validated in vivo efficacy, and robust chemical profile enable reproducible findings across cell-based and animal models. Future research may focus on integrating Rotigotine with advanced neuropharmacological platforms and dissecting secondary receptor contributions. For detailed product specifications and ordering, consult the Rotigotine A3776 product page from APExBIO.